Dr. Michael Link, MD
Palo Alto, CA
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Link, Pediatric Hematologist-Oncologist in Palo Alto, CA?
Dr. Michael Link, MD is a Pediatric Hematologist-Oncologist, who primarily practices in Palo Alto, CA. He is board certified. Dr. Link completed his residency at Children'S Hosp, Hematology-Internal Medicine; Children'S Hosp, Immunology; Children'S Hosp, Pediatrics and is currently affiliated with Childrens Hospital At Stanford. Dr. Link is fluent in English and Spanish, and is currently seeing new patients. Dr. Link’s practice accepts Kaiser Permanente, Medicare, Aetna, Cigna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Link’s office at (650) 497-8000.
What are Areas of Expertise for Dr. Link?
Dr. Michael Link, MD is a highly-rated, board-certified Pediatric Hematologist-Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Link empowers patients to confidently navigate their health journey, specializing in Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin's, Sarcoma, and comprehensive wellness support. Serving the Palo Alto, CA community, Dr. Link is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Link go to medical school and complete their residency?
Fellowship: Children's Hospital Boston, Boston, MA | Dana-Farber Cancer Institute, Boston, MA | Dana-Farber Cancer Institute MA | Children's Hospital Boston MA
Residency: Children'S Hosp, Hematology-Internal Medicine; Children'S Hosp, Immunology; Children'S Hosp, Pediatrics | Children's Hospital Boston
Medical School: Stanford Univ Sch Of Med- Stanford Ca
Is Dr. Link board certified as a Pediatric Hematologist-Oncologist?
Yes, Dr. Michael Link, MD is board certified by the American Board of Pediatrics , American Board of Dermatology , American Board of Dermatology since 1980, American Board of Pediatrics since 1979
What languages does Dr. Link speak?
Dr. Link and their clinical team can communicate with patients in the following languages:
English
Spanish
What conditions does a Pediatric Hematologist-Oncologist like Dr. Link typically treat?
As a Pediatric Hematologist-Oncologist, Dr. Link diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Link. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Hodgkin Lymphoma
- Hodgkin's Disease
- Hodgkin's Lymphoma
ICD-10 Codes:
- C8190: Hodgkin lymphoma, unspecified, unspecified site
- C819A: Hodgkin lymphoma, unspecified, in remission
Also known as:
- Acute Lymphoblastic Leukemia
- Acute Lymphocytic Leukemia in Remission
- Acute Lymphocytic Leukemia
- ALL
- Acute lymphocytic leukemia
- Lymphoblastic leukemia
- ALL Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Childhood Leukemia in Remission
ICD-10 Codes:
- C9100: Acute lymphoblastic leukemia not having achieved remission
- C9101: Acute lymphoblastic leukemia, in remission
Also known as:
- Cancer Chemotherapy
- Chemo treatment
- Oncology chemotherapy
- Cancer drug therapy
ICD-10 Codes:
- Z5111: Encounter for antineoplastic chemotherapy
Also known as:
- Cancer Follow-up Exam
- Cancer
- Post-cancer treatment checkup
- Malignancy surveillance
- Oncology follow-up
ICD-10 Codes:
- Z08: Encounter for follow-up examination after completed treatment for malignant neoplasm
What procedures does a Pediatric Hematologist-Oncologist like Dr. Link typically perform?
As a Pediatric Hematologist-Oncologist, procedures performed by Dr. Michael Link may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Link's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Link accept my insurance?
Dr. Link accepts most major insurance plans. Important: Please call our office at (650) 497-8000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Link accept in Palo Alto, CA?
Dr. Link in Palo Alto, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
California Water Service Group
Cigna Group
CVS Health (formerly Aetna)
Federal government of the United States
Kaiser Permanente
Santa Cruz County
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Link's office located?
Recognitions
Awards
Annual Memorial Lectureship, Pediatric Cancer Research Foundation
Washington University School of Medicine
Ben Abelson Memorial Visiting Professor
Alpha Omega Alpha, Alpha Omega Alpha
21st Annual W.W. Sutow Visiting Lecturer in Pediatric Oncology, MD An
Brent Eley Visiting Professor in Pediatric Oncology,
University of Colorado Cancer Center and the Childrens Hospital, Denve
Phi Beta Kappa
The Royal Academy of Paediatrics and Child Health (June)
Honorary Fellow
Publications
Adolescent and Young Adult Oncology, Version 2.2014
, 2014
Relapse after treatment of pediatric hodgkin lymphoma
, 2013
The Impact of Drug Shortages on Children with Cancer - The Example of Mechlorethamine
, 2012
Extremely low-frequency magnetic fields and survival from childhood acute lymphoblastic leukemia
, 2012
Adolescent and young adult oncology. Clinical practice guidelines in oncology.
, 2012
ALK+ aplastic large cell lymphoma exhibits phosphatidylinositol-3 kise
, 2012
Association Between Radiotherapy vs No Radiotherapy Based on Early Response to VAMP Chemotherapy
, 2012
Chemotherapy Drug Shortages in the United States: Genesis and Potential Solutions
, 2012
Complete Ocular Paresis in a Child with Posterior Fossa Syndrome
, 2012
Second Malignt Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low
, 2010
The Impact of the Privacy Rule on Cancer Research
, 2009
Non-aplastic peripheral T-cell lymphoma in childhood and adolescence
, 2008
Nodular lymphocyte-predomint Hodgkin lymphoma presenting as fulmint hepatic failure in a pediatric
, 2008
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival
, 2008
Treatment of metastatuc Ewing Sarcoma
, 2007
Fil results of a prospective clinical trial with VAMP
, 2007
Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive
, 2007
Magnetic field exposure and prognostic factors in childhood leukemia
, 2007
Magnetic field exposure and long-term survival among children with leukaemia
, 2006
Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis
, 2006
Review of tonsillar lymphoma in pediatric patients from the Pediatric Oncology Group
, 2005
Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and
, 2005
Epstein-Barr virus-associated peripheral T-cell lymphoma
, 2005
High-dose therapy and autologous hematopoietic stem
, 2004
Risk-adapted, combined-modality therapy with VAMP
, 2004
Cyclophosphamide dose intensification during induction therapy for intermediate
, 2004
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone
, 2004
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma
, 2004
tiol Institutes of Health State-of-the-Science Conference Statement: Symptom Magement in Cancer
Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy
, 2003
Presurgical chemotherapy compared with immediate surgery
, 2003
Addition of ifosfamide and etoposide to standard chemotherapy
, 2003
Prognostic factors and clinical outcomes
, 2003
Children from ethnic minorities have benefited equally
, 2002
tiol action plan for childhood cancer: report of the tiol summit meetings on childhood cancer.
, 2002
Assessment of lymphadenopathy in children
, 2002
Minimax two-stage-designs with applications to tissue banking case-control studies
, 2002
Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose
, 2002
VAMP and low-dose, involved-field radiation for children and adolescents with favorable
, 2002
Bone marrow stroma-supported culture of T
, 2002
Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin
, 2002
Phase II/III trial of etoposide and high-dose ifosfamide
, 2002
Efficacy of ifosfamide
, 2001
Which patients with microscopic disease
, 2001
Controversies in the magement of paratesticular rhabdomyosarcoma
, 2001
Presurgical window of carboplatin and surgery and multidrug chemotherapy
, 2001
What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?
, 2001
Thyroid carcinoma after successful treatment of osteosarcoma: A report of three patients
, 2001
Attitudes and practices among pediatric oncologists regarding end-of-life care
, 2001
New recurring cytogenetic abnormalities
, 2000
Benefit of intensified therapy for patients with local or regiol embryol rhabdomyosarcoma
, 2000
Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia
, 2000
Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons
, 2000
Significance of commonly used prognostic factors differs
, 1999
Intensive high-dose asparagise consolidation improves survival for pediatric patients with T cell
, 1999
Treatment of localized primary non-Hodgkin's lymphoma of bone in children
, 1999
Childhood acute lymphoblastic leukemia with the MLL-ENL fusion
, 1999
Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation
, 1999
Treatment of metastatic osteosarcoma at diagnosis: A pediatric oncology group study
, 1998
A multidiscipliry study investigating radiotherapy in Ewing's sarcoma: End results of POG #8346
, 1998
Randomized trial of r
, 1998
E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome
, 1998
Fractioted cyclophosphamide and back to back high dose methotrexate and cytosine arabinoside
, 1997
Treatment of children and young adults with early-stage non-Hodgkin's lymphoma
, 1997
Lack of ETV6 (TEL) gene rearrangements or p16(INK4A)
, 1997
Altered expression of p53
, 1997
A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the
, 1997
Frequent and selective methylation of p15 and deletion of both p15 and p16 in T
, 1997
Case-control study suggests a favorable impact of TEL rearrangement in patients with B
, 1997
Use of an anti-ALK antibody in the characterization of aplastic large-cell lymphoma of childhood
, 1997
NCCN pediatric osteosarcoma practice guidelines. The tiol Comprehensive Cancer Network.
, 1996
Improved survival for children with B-cell acute lymphoblastic leukemia
, 1996
High incidence of potential p53 ictivation
, 1996
Uniform approach to risk classification
, 1996
STAGE-SPECIFIC AND LINEAGE
, 1995
B-CELL LINEAGE CONFERS A FAVORABLE OUTCOME AMONG CHILDREN AND ADOLESCENTS WITH LARGE
, 1995
SAFETY AND EFFICACY OF L-LEUCOVORIN RESCUE FOLLOWING HIGH-DOSE METHOTREXATE FOR OSTEOSARCOMA
, 1995
TREATMENT OF OSTEOSARCOMA WITH IFOSFAMIDE - COMPARISON OF RESPONSE IN PEDIATRIC
, 1995
ABVD/MOPP AND LOW-DOSE INVOLVED-FIELD RADIOTHERAPY
, 1994
HYPNOSIS IN THE PREVENTION OF CHEMOTHERAPY-RELATED USEA AND VOMITING IN CHILDREN
, 1994
FREQUENCY AND PROGNOSTIC-SIGNIFICANCE OF HRX REARRANGEMENTS IN INFANT ACUTE LYMPHOBLASTIC
, 1994
SIMULTANEOUS EXPRESSION OF RBTN-2 AND BCR
, 1994
PRESENTING CHARACTERISTICS OF TRISOMY
, 1994
MIC2 ALYSIS IN PEDIATRIC LYMPHOMAS AND LEUKEMIAS
, 1994
EWINGS-SARCOMA - ROUTINE DIAGNOSTIC UTILIZATION OF MIC2 ALYSIS - A PEDIATRIC-ONCOLOGY-GROUP
, 1994
SECONDARY BREAST-CANCER IN PATIENTS PRESENTING WITH OSTEOSARCOMA
, 1994
HODGKINS-DISEASE IN THE VERY YOUNG
, 1994
IMMUNOCYTOCHEMICAL STUDY OF 12E7 IN SMALL ROUND-CELL TUMORS OF CHILDHOOD
, 1993
DETECTION OF THE (11 22)(Q24 Q12) TRANSLOCATION OF EWINGS
, 1993
HRX INVOLVEMENT IN DENOVO AND SECONDARY LEUKEMIAS WITH DIVERSE CHROMOSOME 11Q23 ABNORMALITIES
, 1993
ACUTE HYPERSENSITIVITY REACTIONS TO ETOPOSIDE IN A VEPA REGIMEN FOR HODGKINS-DISEASE
, 1993
LABORATORY CLINICAL INTERFACE
, 1993
CLINICAL-FEATURES AND OUTCOME OF T
, 1993
A SERINE PROLINE-RICH PROTEIN IS FUSED TO HRX IN T(4-11) ACUTE LEUKEMIAS
, 1993
The multi-institutiol osteosarcoma study: an update.
, 1993
LANGERHANS CELL HISTIOCYTOSIS PRESENTING WITH THE SUPERIOR VE-CAVA SYNDROME - A CASE-REPORT
, 1993
Osteosarcoma in adolescents and young adults
, 1993
A STUDY OF TOXICITY AND COMPARATIVE THERAPEUTIC EFFICACY OF VINDESINE-PREDNISONE VS VINCRISTINE
, 1992
CHILDHOOD MALIGNT NON-HODGKIN LYMPHOMAS OF UNCOMMON HISTOLOGY
, 1992
MORPHOLOGICAL, IMMUNOLOGICAL AND CYTOGENETIC STUDIES IN CHILDREN WITH ACUTE LYMPHOBLASTIC
What is Dr. Link's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Link's National Provider Identifier (NPI) number is 1982742862.
What common questions do patients ask about Dr. Link?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Link
What is Dr. Michael Link's specialty?
Dr. Link is a Pediatric Hematologist-Oncologist near Palo Alto, CA.
What does a Pediatric Hematologist-Oncologist do?
A pediatrician trained in the integration of pediatrics, hematology, and oncology, specializing in the recognition and management of blood disorders and cancer in children. This expert provides comprehensive care for conditions such as anemia, bleeding disorders, and various pediatric cancers.
Is this Dr. Michael Link affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Link is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Pediatric Hematologist-Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Pediatric Hematologist-Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Michael Link accepting new patients in Palo Alto, CA?
Yes, Dr. Michael Link is accepting new patients at this time.
Does Dr. Michael Link offer online booking?
Please contact Dr. Link's office at (650) 497-8000 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Michael Link?
Please contact Dr. Link's office at (650) 497-8000 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Michael Link have?
Dr. Michael Link is certified by the American Board of Pediatrics and American Board of Dermatology.
Other Pediatric Hematologist-Oncologist Near Palo Alto, CA
Pediatric Hematologist-Oncologist
Accepting patients
Pediatric Hematologist-Oncologist
Accepting patientsPediatric Hematologist-Oncologist
Accepting patients